Reactive oxygen species and aldehyde dehydrogenase 1A as prognosis and theragnostic biomarker in acute myeloid leukaemia patients

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to assess the prognostic value of reactive oxygen species (ROS) and aldehyde dehydrogenase 1A in acute myeloid leukaemia (AML).
Patients received first-line therapy with monitoring of ROS levels and ALDH1A1/2 activity.
ABD-3001, an ALDH inhibitor, was tested for its efficacy against leukaemic blasts.
Safety and efficacy of ABD-3001 assessed in multicenter phase 1 trial ODYSSEY (NCT05601726).
Increased ROS levels were significantly associated with refractory leukaemic blasts (p = 0.015).
ALDH1A1/2 activity correlated with leukaemic cell proliferation and redox balance (p = 0.0273).
ROS levels were identified as a significant predictive factor for sensitivity to ABD-3001 (p < 0.05).

Demonstrates the role of ROS and ALDH1A in predicting outcomes in acute myeloid leukaemia, suggesting new therapeutic directions.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Venton et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

Share